On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

Zenosense, Inc. (ZENO) Attracts Investment Funds for Next Step in Development of MIDS Cardiac Point of Care Diagnostic Device

Agreement signed with third party investor to fund up to $1.2 million to support next crucial development phase of MIDS Cardiac POC diagnostic device Patented MIDS technology has successfully detected commercial assay beads at a level approximately four times better than the threshold advised as required for a high sensitivity troponin assay Cardiac biomarkers global … Continue reading “Zenosense, Inc. (ZENO) Attracts Investment Funds for Next Step in Development of MIDS Cardiac Point of Care Diagnostic Device”

QualityStocksNewsBreaks – Zenosense, Inc. (ZENO) MML JV Expands Technical Team

Healthcare technology company Zenosense (OTC: ZENO) this morning announced that, in support of the next phase of development of MIDS Cardiac, its MIDS Medical Ltd. (“MML”) joint venture (“JV”) has expanded its technical team. MML has engaged three key contractors following its recent funding agreement. Two such contractors are independent electronics engineers with experience including … Continue reading “QualityStocksNewsBreaks – Zenosense, Inc. (ZENO) MML JV Expands Technical Team”

QualityStocksNewsBreaks – Zenosense, Inc. (ZENO) MIDS Cardiac Device Could Spare Patients from Unnecessary Evaluation Expenses

Healthcare technology company Zenosense (OTC: ZENO), a co-owner of the United Kingdom’s MIDS Medical Limited (“MML”) and its innovative handheld MIDS technology, is engaged in the ongoing development of its innovative MIDS Cardiac device. A recent article about the company reads: “MIDS Cardiac aims is to deliver true laboratory accuracy, performing high-sensitivity troponin tests in … Continue reading “QualityStocksNewsBreaks – Zenosense, Inc. (ZENO) MIDS Cardiac Device Could Spare Patients from Unnecessary Evaluation Expenses”

Zenosense, Inc.’s (ZENO) Heart Attack Testing Technology Development Continues to Advance Hopes of Portable Point of Care Device

Company’s MIDS Cardiac device aims to help ER personnel perform quick, high-sensitivity analysis of heart events MIDS device’s handheld portability is being developed to allow quick-response resource to minimally trained ambulance personnel Final device could ultimately help save patients, health insurers from unnecessary evaluation expenses Heart disease remains the leading cause of death in men … Continue reading “Zenosense, Inc.’s (ZENO) Heart Attack Testing Technology Development Continues to Advance Hopes of Portable Point of Care Device”

QualityStocksNewsBreaks – Zenosense, Inc. (ZENO) MIDS Medical Ltd. JV Secures Up to $1.2M in Staged Funding

Zenosense (OTC: ZENO), a healthcare technology company, this morning announced that its MIDS Medical Ltd. (“MML”) joint venture (“JV”) has entered a staged funding for the next phase of development of the MIDS Cardiac™ hand-held technology. MML entered into an agreement with a third-party investor for funding of up to a total of $1,200,000 on … Continue reading “QualityStocksNewsBreaks – Zenosense, Inc. (ZENO) MIDS Medical Ltd. JV Secures Up to $1.2M in Staged Funding”

QualityStocksNewsBreaks – Zenosense, Inc.’s (ZENO) MIDS Cardiac™ Uniquely Designed to Provide Lab-Comparable Accuracy in Minutes at Point of Care

Zenosense’s (OTC: ZENO) MIDS Cardiac™ may prove revolutionary in the niche cardiac diagnostic testing market, currently valued between $2 and $6 billion in the U.S. A recent article discussing this, reads “MIDS Cardiac™ is unique, because the technology is being developed to detect very low levels of cardiac markers to deliver accuracy that’s equal or … Continue reading “QualityStocksNewsBreaks – Zenosense, Inc.’s (ZENO) MIDS Cardiac™ Uniquely Designed to Provide Lab-Comparable Accuracy in Minutes at Point of Care”

MIDS Cardiac by Zenosense, Inc. (ZENO): A Heart Attack Diagnostic Revolution?

The handheld testing device technology under development by Zenosense aims to deliver rapid results and state-of-the-art, laboratory-accurate results for the quick diagnosis of heart attacks Medical professionals believe that diagnosis within 30 minutes of a heart attack is the golden standard for ensuring adequate treatment Cardiac diagnostic testing market estimated between $2 billion and $6 … Continue reading “MIDS Cardiac by Zenosense, Inc. (ZENO): A Heart Attack Diagnostic Revolution?”

QualityStocksNewsBreaks – Zenosense, Inc. (ZENO) Transforming Modern Cardiac Diagnostics

Zenosense (OTC: ZENO), through the development of MIDS Cardiac™, seeks to provide a technology that delivers laboratory-level accuracy at the point of care. An article discussing the company’s recent success reads: “A successful development of MIDS Cardiac is just the first step in the development of a wider technology platform that could be adapted to … Continue reading “QualityStocksNewsBreaks – Zenosense, Inc. (ZENO) Transforming Modern Cardiac Diagnostics”

Zenosense, Inc. (ZENO) Aims to Revolutionize Cardiac Diagnostics Market

Handheld technology platform in development to deliver high sensitivity, laboratory accuracy testing for cardiac biomarkers at the point of care Cardiac biomarker testing market expected to reach $7.2 billion this year Major potential for the patented technology to be applied to the detection of numerous other conditions, including cancer, HIV, hepatitis, autoimmune diseases and many … Continue reading “Zenosense, Inc. (ZENO) Aims to Revolutionize Cardiac Diagnostics Market”

QualityStocksNewsBreaks – Zenosense, Inc. (ZENO) Continues to Reach Key Milestones

Zenosense (OTC: ZENO) is an innovative healthcare technology developer engaged in transformational, disruptive medical diagnostic projects. Recently, the company has achieved two major milestones. An article discussing the company’s recent success reads: “Health care technology company Zenosense, Inc. (OTCQB: ZENO) has completed two important milestones recently. The first was a successful second round of quantitative … Continue reading “QualityStocksNewsBreaks – Zenosense, Inc. (ZENO) Continues to Reach Key Milestones”

Market Basics

New to the micro-cap markets?Get answers to your questions about investing in Small-Cap / Micro-Cap Stocks and learn how to protect yourself.

The Basics

Newsletter Publishers

Have an up and coming newsletter and want to be included in our coverage list? Looking to get more coverage and grow subscriptions? Register for coverage.

Register

Public Companies

Are you a Small-Cap / Micro-Cap company looking for coverage? We'd love to hear from you. Fill out our quick contact form or send us a text.

Get Covered